- Home
- ALDX vs RCS Comparison
ALDX vs RCS Comparison
Compare ALDX & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- RCS
- Stock Information
- Founded
- ALDX 2004
- RCS 1994
- Country
- ALDX United States
- RCS United States
- Employees
- ALDX N/A
- RCS N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- ALDX Health Care
- RCS Finance
- Exchange
- ALDX Nasdaq
- RCS Nasdaq
- Market Cap
- ALDX 313.4M
- RCS 354.7M
- IPO Year
- ALDX 2014
- RCS N/A
- Fundamental
- Price
- ALDX $5.60
- RCS $7.85
- Analyst Decision
- ALDX Strong Buy
- RCS
- Analyst Count
- ALDX 2
- RCS 0
- Target Price
- ALDX $9.50
- RCS N/A
- AVG Volume (30 Days)
- ALDX 715.8K
- RCS 141.1K
- Earning Date
- ALDX 11-06-2025
- RCS 01-01-0001
- Dividend Yield
- ALDX N/A
- RCS 10.12%
- EPS Growth
- ALDX N/A
- RCS N/A
- EPS
- ALDX N/A
- RCS N/A
- Revenue
- ALDX N/A
- RCS N/A
- Revenue This Year
- ALDX N/A
- RCS N/A
- Revenue Next Year
- ALDX $36.23
- RCS N/A
- P/E Ratio
- ALDX N/A
- RCS N/A
- Revenue Growth
- ALDX N/A
- RCS N/A
- 52 Week Low
- ALDX $1.14
- RCS $4.51
- 52 Week High
- ALDX $7.20
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- ALDX 59.73
- RCS 67.18
- Support Level
- ALDX $5.13
- RCS $7.58
- Resistance Level
- ALDX $5.78
- RCS $7.94
- Average True Range (ATR)
- ALDX 0.23
- RCS 0.13
- MACD
- ALDX 0.06
- RCS 0.03
- Stochastic Oscillator
- ALDX 84.00
- RCS 77.50
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.